VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

autologous dendritic cell vaccine (DCV)
Vaccine Information
  • Vaccine Name: autologous dendritic cell vaccine (DCV)
  • Target Pathogen: Cancer
  • Target Disease: Cancer
  • Vaccine Ontology ID: VO_0007282
  • Type: Dentritic Cell
  • Status: Clinical trial
  • Immunization Route: Intramuscular injection (i.m.)
  • Description: This vaccine has been used in clinical trials involving ovarian serous carcinoma, glioblastoma and cutaneous melanoma. (Baldueva et al., 2012; Hu et al., 2022; Sarivalasis et al., 2019)
Host Response

Human Response

  • Vaccine Immune Response Type: VO_0003057
  • Immune Response: Immunologic monitoring showed correlation of T- and B-cell immune response with DCV clinical efficacy (p<0,05) (Baldueva et al., 2012).
References
Baldueva et al., 2012: Baldueva IA, Novik AV, Moiseenko VM, Nekhaeva TL, Danilova AB, Danilov AO, Protsenko SA, Petrova TIu, UleÄ­skaia GI, Shchekina LA, Semenova AI, MikhaÄ­lichenko TD, Teletaeva GM, Zhabina AS, Volkov NV, Komarov IuI. [Phase II clinical trial of autologous dendritic cell vaccine with immunologic adjuvant in cutaneous melanoma patients]. Voprosy onkologii. 2012; 58(2); 212-221. [PubMed: 22774527].
Hu et al., 2022: Hu JL, Omofoye OA, Rudnick JD, Kim S, Tighiouart M, Phuphanich S, Wang H, Mazer M, Ganaway T, Chu RM, Patil CG, Black KL, Shiao SL, Wang R, Yu JS. A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022; 28(4); 689-696. [PubMed: 34862245].
Sarivalasis et al., 2019: Sarivalasis A, Boudousquié C, Balint K, Stevenson BJ, Gannon PO, Iancu EM, Rossier L, Martin Lluesma S, Mathevet P, Sempoux C, Coukos G, Dafni U, Harari A, Bassani-Sternberg M, Kandalaft LE. A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma. Journal of translational medicine. 2019; 17(1); 391. [PubMed: 31771601].